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Melanoma prognosis is dictated by tumor-infiltrating lymphocytes, the migratory and
functional behavior of which is guided by chemokine or cytokine gradients. Here, we
retrospectively analyzed the expression patterns of 9 homing receptors (CCR/CXCR) in
naive and memory CD4+ and CD8+ T lymphocytes in 57 patients with metastatic melanoma
(MMel) with various sites of metastases to evaluate whether T cell CCR/CXCR expression
correlates with intratumoral accumulation, metastatic progression, and/or overall survival
(OS). Homing receptor expression on lymphocytes strongly correlated with MMel
dissemination. Loss of CCR6 or CXCR3, but not cutaneous lymphocyte antigen (CLA), on
circulating T cell subsets was associated with skin or lymph node metastases, loss of
CXCR4, CXCR5, and CCR9 corresponded with lung involvement, and a rise in CCR10 or
CD103 was associated with widespread dissemination. High frequencies of CD8+CCR9+
naive T cells correlated with prolonged OS, while neutralizing the CCR9/CCL25 axis in
mice stimulated tumor progression. The expansion of CLA-expressing effector memory
CD8+ T cells in response to a single administration of CTLA4 blockade predicted disease
control at 3 months in 47 patients with MMel. Thus, specific CCR/CXCR expression
patterns on circulating T lymphocytes may guide potential diagnostic and therapeutic
approaches.
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Introduction
Metastatic melanoma (MMel) therapy has been revolutionized by 
the recent availability of BRAF inhibitors and immune checkpoint 
blockers. However, there is still a need for prognostic or predictive 
factors aimed at guiding the clinical management of metastases.
Chemokines are critical regulators of leukocyte traffick­
ing and immune functions (1). They act on G protein–coupled 
receptors, which are abundantly expressed in a variegated man­
ner on all immune cells to regulate their migration and differ­
entiation (2). The magnitude and duration of the signal depend 
on the intensity of the exposure to chemokines and on subse­
quent chemokine receptor desensitization, phosphorylation, 
and internalization (3). The human chemokine system consists 
of 23 receptors and 48 ligands (4). The chemokine receptor–
ligand interaction is redundant, in that chemokine receptors 
can be activated by several chemokines, while a given chemo­
kine can bind multiple receptors. Immune responses guided 
by chemokine receptor signaling represent a complex network 
of regulations at different levels. At the systemic level, there 
is a spatiotemporal and geographic, tissue­specific expression 
of chemokine receptors and their respective ligands. At the 
cellular level, coexpression of several chemokine receptors 
with other immune regulators determines the final functional 
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mainly for 3 markers (CD8+CCR6+ effector memory T cells 
[TEMs], CD4+CCR10+ TCMs and TEMs, and CD8+CCR9+ naive 
T cells [TNs]); (c) an upregulation of CXCR3, CXCR4, CD103, 
and CLA expression in terminally differentiated (T effector mem­
ory cells expressing CD45RA [TEMRAs]) TILs compared with 
that detected in circulating T cells; (d) a functional role of the 
CCR9/CCL25 axis in mice and patients bearing tumors; and (e) 
pharmacodynamic biomarkers of response to ipilimumab such as 
circulating numbers of CLA+CD8+ TEMs.
Results
Chemokine receptor expression patterns. We performed flow 
cytometric analyses of peripheral blood CD4+ and CD8+ T cell 
subsets based on their expression of CCR7 and CD45RA, which 
allowed us to distinguish TNs (CCR7+CD45RA+), TEMRAs 
(CCR7–CD45RA+), TEMs (CCR7–CD45RA–), and TCMs (CCR7+ 
CD45RA–) and then to assess, for each subset, the expression 
(9 homing receptors) or coexpression (23 combinatorions in 
pooled CD4+ or CD8+ T cells) of a variety of CC and CXC recep­
tors (Supplemental Table 1 and Supplemental Figure 1; supple­
mental material available online with this article; doi:10.1172/
JCI80071DS1) in 57 patients with stage IIIB-C or stage IV mel­
anoma (Supplemental Table 2 and Supplemental Figure 2) com­
pared with 26 healthy volunteers (HVs).
Correlation matrices indicated similar chemokine receptor 
expression on CD4+ and CD8+ T cells, except for CXCR4 and 
CD103, and concordant patterns in TNs, TEMs, and TCMs, and 
TEMRAs (Supplemental Figure 3). In accordance with previous 
reports, skin­homing receptors (CCR10 and CLA) and functional 
receptors (CXCR3 on Th1 and CCR6 on Th17) appeared to be asso­
ciated with each other, as indicated on the planar representation 
of the correlation matrix of chemokine receptors obtained for all 
samples analyzed in this study. However, unexpectedly, we found 
no correlation between CD103 and CCR9 expression (Figure 1).
Orchestration of chemokine receptor expression patterns accord-
ing to melanoma metastatic spreading. The organization pattern of T 
cell CCR/CXCR expression was not randomly distributed among 
patient groups but rather mirrored metastatic spreading. Of 104 
parameters, 62 were found to differ significantly (FDR <0.1) 
among patients bearing metastases in distinct locations. Expres­
sion levels were normalized with respect to those of HVs, indicat­
ing that specific signatures could identify preferential metastasis 
to skin and LNs (Cut + LN), lung, or other distant organs (Multi 
mets), without (Multi), or with lung involvement (Multi + lung) 
(Figure 2A). Loss of CXCR3 or CCR6 expression on both CD4+ 
and CD8+ T cells was associated with s.c. or secondary lymphoid 
organ metastases (Figure 2, A and B).
We observed a 4­ to 8­fold decrease in the percentages of 
circulating (a) CXCR3+ TCMs, (b) CD8+CCR6+ memory T cells, 
and (c) CXCR3/CCR6–coexpressing CD4+ T cells in patients 
with MMel compared with that seen in HVs (Figure 2B). Loss of 
CXCR4 or CCR9 expression on both CD4+ and CD8+ T cells as 
well as a drop in CXCR5 expression levels on CD4+ and CD8+ TNs 
compared with HVs indicated lung dissemination (Figure 2C). 
Loss of CXCR4 expression on CD4+ and CD8+ TEMs was asso­
ciated with patients who had pulmonary lesions. Similarly, lung 
tumor deposits were associated with decreased CCR9 expression 
outcome. At the molecular level, signaling through a given 
chemokine receptor may be fine tuned by different ligands 
and intracellular proteins (2). Adding more complexity to the 
system, chemokine receptor signaling can be affected by gly­
coaminoglycans, which may alter the affinities of their ligands, 
as well as by scavenger molecules (2). Chemokine receptors 
have been classified as XC, CC, CXC, and CX3C receptors on 
the basis of the chemokine subclass ligand to which they bind. 
Chemokine expression patterns affect the pathophysiology of 
major diseases, such as cancer (5), inflammation (6), allergy, 
transplantation, and infections, as they influence the migration 
of various T lymphocyte subpopulations to specific tissues and 
polarize T cell function. Chemokine receptors identify func­
tional subsets within the human peripheral CD4+ and CD8+ T 
cell pool. In response to TCR stimulation or homeostatic cyto­
kines, CXCR3+ or CCR4+CD4+ central memory T cells (TCMs) 
fully differentiate into CCR7– Th1 and Th2 cells, respectively 
(7). A population of human skin­homing memory CD4+ T cells 
expressing the chemokine receptors CCR10, CCR6, and CCR4 
produce IL­22, but these cells do not produce IL­17 or IFN­γ 
(8). CCR4 is also highly expressed in a major fraction of blood 
α4β7– CD4+ TCMs, including almost all skin memory CD4+ 
cells expressing cutaneous lymphocyte antigen (CLA). Approx­
imately 25% of human peripheral blood TCMs express the 
CXCR5 chemokine receptor, a hallmark of follicular Th cells. 
CXCR5+ TCMs express high levels of the chemokine CXCL13 
and efficiently induce Ig secretion. These cells are character­
ized by a high responsiveness to ICOS ligand costimulation, 
leading to IL­10 release (9).
The prognosis of a variety of human malignancies, such as 
melanoma (10), colorectal cancer (11), and ovarian cancer (12), 
is dictated by the abundance, spatial trafficking, and quality of 
intratumoral T cell infiltrates (13). Gene expression profiling per­
formed on a series of MMels and other malignancies revealed a 
major segregation of samples based on the presence of T cell–
associated transcripts correlating with the expression of defined 
chemo kine genes (5, 14). Immune­mediated regression of mel­
anoma, whether spontaneous or therapy induced, supposedly 
relies on the elicitation of antitumor effector Th1 and Th17 or 
pathogenic Th17 (pTh17) cells and their subsequent homing to 
malignant lesions.
Salerno et al. (15) recently studied whether T cell expression 
of the chemokine receptors CCR4, CCR5, and CXCR3 and inte­
grins could account for T cell retention in MMel lesions. With 
the exception of bowel metastases, in which T cells showed high 
expression levels of CCR9, we observed a limited tissue site–spe­
cific homing to human melanoma metastases. We revisited this 
notion and performed retrospective analyses of the phenotype 
and functions of circulating T lymphocytes and tumor­infiltrat­
ing lymphocytes (TILs) from tumoral lymph nodes (LNs) in 3 
independent cohorts of MMel patients treated before the era of 
efficient therapies, with the aim of correlating homing receptor 
expression with the pattern of metastatic spreading (skin and 
LNs, lung, distant organs, with or without lung dissemination) 
and overall survival (OS). We found (a) an orchestrated deregu­
lation of CCR/CXCR expression according to the various sites 
of disease dissemination; (b) substantial correlations with OS, 
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ation status of primitive tumors (Supplemental Figure 4, C and 
D). Polymetastatic locations were also associated with a loss of 
effector cells. Hence, a more than 4­fold decrease in CXCR3+ 
TCMs, TEMs, and TEMRAs (Figure 2B) as well as CD8+CXCR4+ 
TEMs, TEMRAs, and CD4+CCR9+ TEMRAs (Figure 2C) was 
associated with distant metastases. Interestingly, CXCR5 alone 
or in association with CD103 on both CD4+ and CD8+ T cells 
allowed the distinction of lung­free disseminated disease, in that 
there was a greater than 2­fold increase in the number of these 
cells in the blood of patients presenting with distant metastases 
without lung involvement (Figure 2C).
We conclude that CCR/CXCR chemokine expression patterns 
on peripheral T lymphocytes correlate with metastatic dissemina­
tion during melanoma progression.
LN metastases–associated chemokine receptors, lymphocyte func-
tions, and prognosis. Loss of circulating CD8+CCR6+ TEMs is one 
hallmark of patients with skin and LN metastases (Figure 2B and 
Figure 3A). This loss could not be explained by preferential traf­
on almost all CD4 and CD8 T cell subsets, including CXCR5/
CCR9­coexpressing T cells. Moreover, a 2­ to 4­fold decrease in 
CRTH2 and CCR6 expression on CD8+ T cells in MMel patients 
compared with HVs was observed when lung metastases were 
diagnosed (Figure 2C).
As a general pattern, oligometastatic spread (skin and LN or 
lung) was associated with decreased CCR/CXCR expression on 
effector and memory T lymphocytes, while polymetastatic dis­
semination favored the increase in CCR/CXCR expression on 
naive T lymphocytes. A rise in the number of CD4+CD103+ and 
CD4+CCR10+ TNs as well as CCR10 and CRTH2 CD4+ T cells 
and CCR10 and CXCR4 CD8+ T cells indicated wide spreading 
of melanoma (Figure 2D). A rise in expression of CRTH2 and 
CXCR3 in pooled CD4+ T cells was also observed (Figure 2D). Of 
note, an increase in CD4+CD103+ TNs was strongly associated 
with liver metastases (but not in bone, brain, or gut locations, 
Supplemental Figure 4, A and B). Moreover, CD103 expres­
sion with CCR9 or CXCR5 was also associated with the ulcer­
Figure 1. Planar maximally filtered graph representation of the matrix of correlation among the 104 parameters used in this study. Interconnecting 
lines are in red or green if the 2 nodes were positively and negatively correlated, respectively. Ellipses represent 4 groups of chemokine receptors associ-
ated with the metastatic spreading pattern described in Figure 2.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
9 2 4 jci.org   Volume 126   Number 3   March 2016
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
9 2 5jci.org   Volume 126   Number 3   March 2016
Altogether, since CXCR3 and CCR6 expression on CD4+ 
and CD8+ T cells correlated with each other (Figure 1 and Sup­
plemental Figure 3), we propose that a significant drop in CCR6+ 
and CXCR3+ TCM numbers (the dominant subset in terms of 
numbers; Figure 2) represents a hallmark of metastatic dissem­
ination into LNs.
Lung metastases–associated chemokine receptors, lymphocyte 
functions, and survival. Eleven melanoma patients presented 
with metastases in the lung, skin, and LNs. Circulating CD4+ 
TEM, TEMRA, and TCM lymphocytes from these patients 
showed reduced CXCR4 expression levels (Supplemental Fig­
ure 6, A and B, and data not shown). CD4+CXCR4+ TEMRAs 
tended to accumulate in LNs infiltrated by melanoma cells 
(Supplemental Figure 6C). Even more specific to isolated lung 
metastases, CXCR5 expression was reduced in circulating 
CD4+ TEMRAs or CD4+CCR9+ T cells (Supplemental Figure 7, 
A and B, and data not shown). Cells with this phenotype did not 
accumulate in metastatic LNs (Supplemental Figure 7C). They 
exhibited a Th1 cytokine production profile upon TCR engage­
ment (Supplemental Figure 7D). Importantly, CCR9 in circulat­
ing CD4+ (not shown) and CD8+ TNs was strongly decreased 
in patients with lung metastases (Figure 2C and Figure 4A) but 
rarely accumulated in metastatic LNs (Figure 4B). High levels 
of circulating CCR9+CD8+ TNs were associated with a favorable 
prognosis (Figure 4C, using localization group–adjusted con­
tinuous variables [P = 0.0084]; median values [P < 0.0001], or 
tertile values [P = 0.0009] as cut­offs or using stage­adjusted 
values [P = 0.0036]). Of note, the numbers of CRTH2/CCR6­
coexpressing CD8+ T cells were also reduced in patients with 
lung metastases (Figure 2C).
Altogether, loss of CXCR4, CXCR5, and CCR9 in TNs appears 
to be a hallmark of metastatic dissemination into lungs.
Distant metastases–associated chemokine receptors, lym-
phocyte functions, and survival. Melanoma dissemination is 
associated with a major loss of CXCR3 in CD4+ TCMs, TEMs, 
and TEMRAs (>4­fold, Figure 2B) as well as of CD4+CCR9+ 
TEMRAs and CD8+CXCR4+ TEMs and TEMRAs (Figure 2C). 
In parallel, a broad spectrum of metastases was accompanied 
with a significant rise in circulating CD4+CCR10+ TNs, TCMs, 
and TEMs (Figure 2D, Figure 5A, and data not shown) and 
CCR10+CRTH2+, CCR10+CXCR3+, or CRTH2+CXCR3+ CD4+ 
T cells (Supplemental Figure 8, A–C). CD4+CCR10+ TCMs and 
TEMs were severely reduced in melanoma LN metastases (Fig­
ure 5B), and circulating cells expressed higher levels of IL­9, 
IL­4, and IL­10, but low levels of Th1 cytokines in polymeta­
static patients (Figure 5C). Low frequencies of CCR10+CD4+ 
TCMs (data not shown) and TEMs were associated with pro­
longed survival (Figure 5D, using localization group–adjusted 
median values [P = 0.0185] or tertile values [P = 0.0083] as 
cut­offs). Moreover, CLA+CCR10+ T cells were reduced in 
metastatic LNs (Figure 5E). Circulating CLA+CCR10+ T cells 
expressed higher levels of IL­5, IL­9, IL­10, and IL­13 (Fig­
ure 5F). Reduced numbers of circulating CCR10+CLA+ T cells 
predicted a prolonged OS (considered a continuous variable, 
adjusted according to localization group [P = 0.0359], with the 
median as the cut­off value, adjusted according to localiza­
tion group [P = 0.0272], and tertiles as cut­off values, adjusted 
ficking and accumulation of such cells to the affected LNs, which 
contained fewer CD8+CCR6+ TEMs than did the blood (Figure 
3B). However, when the tumor continued to invade distant organs, 
not just the lungs, this cell population marker increased to reach 
the levels found in HVs (Figure 3A). Flow cytometry–based cell 
sorting of circulating CD8+CCR6+ T cells revealed that such cells 
expressed less IL-2, IL-5, IL-13, and TNF­α (but similar levels of 
IFN­γ) as compared with the levels in CD8+CCR6– control T cells 
(Figure 3C). Low frequencies of circulating CD8+CCR6+ TEMs 
were associated with prolonged survival (considered a continuous 
variable, adjusted according to localization group, P = 0.0317; with 
the median as a cut­off value, adjusted according to localization 
group, P = 0.0305; with tertiles as cut­off values, adjusted accord­
ing to localization group, P = 0.0313; and adjusted according to 
stage, P = 0.0235, Figure 3D.
A significant decrease in the frequency of circulating 
CD4+CXCR3+ and CD8+CXCR3+ TNs and TCMs as well as 
CXCR3+CCR6+ double­positive CD4+ T cells was the second fin­
gerprint of cutaneous and LN (and other) metastases (Figure 
2B and Figure 3, E and F). CD4+CXCR3+ T cells accumulated in 
metastatic LNs, perhaps explaining their decrease in the blood 
(Figure 3G). As already reported in the context of MMel, CXCR3+ 
T cells have a Th1 profile, home to inflammatory lesions, and are 
expanded by vaccine adjuvant–based immunotherapies (16–18). 
In the present study, high circulating levels of CD4+CXCR3+ TEMs 
indicated a favorable prognosis for MMel patients (considered with 
the median for the cut­off value, adjusted according to localization 
group, P = 0.0123, or according to stage, P = 0.0121, Figure 3H).
Unexpectedly, CLA expression on circulating T cells was 
not modulated by skin or LN metastatic dissemination (Sup­
plemental Figure 5, A and B), although CLA+CD4+ TEMRAs 
accumulated in LN tumors (Supplemental Figure 5, C and D). 
In the polymetastatic configuration, the numbers of CD4+CLA+ 
TEMRAs or CD8+CLA+ TCMs eventually increased in the blood 
(Supplemental Figure 5, A and B).
Figure 2. Nonhierarchical clustering of the expression of CCR and CXCR 
studied in circulating T cells from patients with MMel after normaliza-
tion to HV-related values. (A) Heatmap representing 62 markers that 
were found significantly altered among patient groups at an FDR below 
0.1. Each cell depicts the fold change between the metastatic group and 
a cohort of HVs (n = 26): red indicates an increase and green a decrease 
in marker levels compared with those in the reference population. The 
dendrogram classifies 57 patients (featured according to their meta-
static dissemination patterns at diagnosis) for CCR and CXCR expres-
sion on all 4 subsets of CD4+ and CD8+ T lymphocytes (featured for each 
marker), highlighting that most chemokine receptor families segregated 
according to metastatic spreading (summarized at the bottom), with a 
decrease (green) or increase (red) in peripheral blood levels compared 
with those in HVs. From left to right: primary sites of invasion (skin and 
LNs), followed by additional locations of metastatic spreading (such 
as to lungs and other distant organs). As for liver metastases, CD103 
upregulation may constitute a hallmark (Supplemental Figure 4). Pts, 
patients. (B–D) log2-based fold changes (and 95% CI) in parameter levels 
between the metastatic groups and the HV cohort for the 62 markers 
found altered among the patient groups. Markers that were significantly 
associated with patient prognosis (detailed in the subsequent figures) 
are highlighted in red. Asterisks indicate significance (as compared with 
HVs), after adjusting for multiple tests: †P < 0.1, *P < 0.05, **P < 0.01, 
and ***P < 0.001, by beta regression.
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according to localization group [P = 0.0060]; Figure 5G). Inter­
estingly, as with CXCR5, CD103 expression on CD4+ T cells 
correlated with distant metastases outside of the lung (Supple­
mental Figure 9A). CD4+CD103+ T cells exhibited a Lag3­like 
profile (19) characterized by IL­10, TNF­α, and IL­2 production 
(Supplemental Figure 9B), failed to accumulate in LN tumor 
lesions (Supplemental Figure 9C), and did not express FOXP3 
(Supplemental Figure 9D). In addition, the frequencies of circu­
lating CD4+CXCR4+CCR10+ T cells were selectively decreased 
in patients with lung metastases but were increased in patients 
with widespread dissemination (Figure 2C).
In summary, a concomitant rise in CCR10 and CD103 in 
naive or memory CD4+ T cells with a decrease in CCR9, CXCR4, 
or CXCR3 TEMs or TEMRAs are hallmarks of distant metastases.
Significant changes during immune checkpoint blockade by ipil-
imumab. CTLA4 blockade by the FDA­approved and the Euro­
pean Medicines Agency–approved (EMA­approved) drug ipili­
mumab induces significant and prolonged (>7 years) antitumor 
effects in approximately 20% of patients with MMel (20, 21). We 
analyzed all the CC and CXC chemokine receptors described 
herein (Supplemental Table 1) in 47 patients diagnosed with 
stage IV MMel who were treated with ipilimumab (mainly 3 
mg/kg [87%]) and enrolled at 4 clinical centers (Supplemental 
Table 3). Interestingly, although we analyzed most of the above­
detailed markers were, we found that only CLA expression on 
CD8+ TEMs (cell numbers, shown in Figure 6A, as well as pro­
portions, shown in Figure 6B), and not on the CD4 T cell pop­
ulation (Figure 6, C and D) monitored after 1 injection of ipil­
imumab, was significantly associated with clinical responses, 
as evaluated according to Response Evaluation Criteria In Solid 
Tumors (RECIST) criteria 3 months after treatment commence­
ment and taking into account the inter­center variations (Figure 
6A, left and right panels, AUC = 0.84; and Figure 6B, left and 
right panels, AUC = 0.75).
Altogether, we found that CTLA4 blockade modulated the 
numbers and/or proportions of CLA+ TEMs, and such changes 
might constitute pharmacodynamic markers or predictors of ther­
apeutic response.
Relevance of CCR9 expression by T cells in a spontaneous mela-
noma model. Transgene­enforced expression of the Ret protoon­
cogene under control of the metallothionein 1 promoter drives 
spontaneous melanomagenesis. This model mimics human 
melanoma progression, in that the primary melanoma lesions 
develop along with LN metastases and invade the bone marrow 
and multiple distant organs. In the Ret­Tg melanoma model, 
TRP2­specific TEMs can be monitored at early stages (in pri­
mary tumors, metastatic LNs, and bone marrow) before chronic 
inflammatory processes promote the accumulation of mye­
loid­derived suppressor cells and Tregs and tumor progression 
in an uncontrolled fashion (22–26).
We took advantage of this well­characterized model to ana­
lyze CCR9 and CXCR3 expression on TILs from primary and 
LN metastatic lesions, bearing in mind that these 2 chemokine 
receptors are associated with prognosis in humans. The propor­
tions of CXCR3+CD4+ TEMs and TCMs decreased in metastatic 
LNs (Figure 7A) compared with the proportions observed in the 
spleen, exactly as was observed in the MMel patients (Figure 3, E 
and F). CCR9+CD8+ TNs accumulated in primary lesions, recir­
culated to the spleen (Figure 7B), and were inversely correlated 
with tumor size (Figure 7C), paralleling the observation that the 
frequency of circulating CCR9+CD8+ TNs was correlated with the 
OS of MMel patients (Figure 4C). To further elucidate the clinical 
significance of the CCR9/CCL25 axis in cancer bearers, we neu­
tralized the murine CCL25 chemokine using a specific Ab in mice 
bearing MCA205 sarcoma. This transplantable tumor model was 
selected on the basis of the high levels of CCL25 released into the 
MCA205 tumor microenvironment of the primary tumor in vivo 
(Figure 7D), levels that were much higher than those in the small 
intestine (Figure 7D). Systemic administration of the neutralizing 
anti­CCL25 Abs was rapidly (by day 6) capable of accelerating 
tumor outgrowth (compared with neutralizing anti­CXCR3 Ab), 
while blocking CXCR3 interfered at later stages (at day 17) of nat­
ural tumor immunosurveillance (Figure 7E). Moreover, neutraliza­
tion of CCL25 or CXCR3 differentially affected the proportions of 
CD4+ and CD8+ T cells in tumor beds (mainly effector T cells; data 
not shown) and tumor­draining LNs, respectively (Figure 7, F and 
G). Hence, the CCL25/CCR9 and the CXCR3/CXCL9-CXCL10­
CXCL11 axes are biologically relevant and act at different levels to 
control the tumor.
Discussion
Despite the recirculation of tumor­specific CD8+ TEMs or TCMs 
in the peripheral blood, MMel progresses by evading immune­
mediated destruction. Since the migratory phenotype of tumor 
antigen–specific T cells determines their antitumor efficacy, 
we hypothesized that the expression of CC or CXC chemokine 
receptors on circulating CD4+ and CD8+ T cells might define the 
phenotypic patterns associated with effective immunosurveil­
lance against melanoma and produce tangible clinical benefit 
(27). Although such research endpoints were already addressed 
in MMel (28, 29), no previous investigation has been as com­
Figure 3. LN metastases–associated chemokine receptor CCR6 and 
CXCR3 expression, function, and survival. (A) CCR6 expression on 
CD8+ TEMs in HVs and in patients presenting with only cutaneous and 
LN metastases (Cut + LN), additional lung involvement, disseminated 
disease (Multi), and in those with metastases in lungs and other distant 
organs (Multi + lung) at the time of inclusion in 1 of the 3 protocols 
described in the Methods. (B) Match-paired comparison of CCR6 expres-
sion (performed by flow cytometry on fresh tissues) in all CD8+  
T cell subsets from blood (B) and tumors (T) at the time of surgery in 
the prospective cohort of 20 patients with MMel. (C) CCR6+CD8+ T cell 
cytokine profile. Flow cytometry–guided sorting based on CCR6 expres-
sion in blood CD8+ T cells from 1 representative patient (out of 2 patients, 
yielding similar results; data represent the mean from duplicate wells) to 
analyze cytokine release after a 40-hour CD3/CD28 mAb–driven stimu-
lation. (D) Kaplan-Meier survival curves representing data from 57 MMel 
patients according to their proportions of circulating CCR6+CD8+ TEMs, 
segregated in tertiles. (E and F) Same as in A, showing expression of the 
CXCR3 subset on CD4 TCMs (E) and TEMs (F). (G) Same as in B, showing 
CXCR3 expression on CD4 T cell subsets. (H) Kaplan-Meier survival curves 
for 57 MMel patients according to the median of the proportions of 
circulating CXCR3+CD4+ TEMs. Each point represents 1 patient specimen, 
and the total number is indicated for all subpopulations studied. Statis-
tical analyses were performed by beta regression (A, E, and F), linear 
mixed-effects (B and G), and Cox regression (D and H) modeling. Raw  
P values are indicated. LRT, likelihood ratio test.
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macrophage–CSF–based (GM-CSF–based) vaccination and to 
traffic to vaccine­induced lesions, correlating with Th1 or T cyto­
toxic 1 (Tc1) immune responses (17, 30). In these vaccine stud­
ies and in the context of psoriasis, CLA and CXCR3 expression 
levels were often associated with CD8+ CTLs and identified a 
subset of cells expressing IFN­γ, T­bet, and IL-12Rβ1 (16). It has 
been suggested that an appropriate Th1­like chemokine pattern 
in melanoma may promote CXCR3+ T cell homing to lesions and 
protect the host against melanoma progression (5, 14). However, 
melanoma infiltration of LNs is insufficient to induce produc­
tion of the CXCR3 chemokines CXCL9, CXCL10, and CXCL11. 
Some melanomas may be capable of secreting chemokines upon 
exogenous stimulation with IFN­α or IFN­γ (31). Despite harbor­
ing a prognostic value in many studies (32, 33), CXCR3 expres­
sion on T cells or CXCL10 release into the tumor microenvi­
ronment does not appear to be a pharmacodynamic marker or a 
predictive factor of response to anti­CTLA4 Abs.
CXCR4 and CCR9 are highly regulated during lung metas­
tasis, and both receptors may facilitate the homing of lympho­
cytes to tumors. CXCR4 expression on CD8+ T cells is inversely 
correlated with CCR10 and CLA expression on CD4+ and CD8+ 
T cells. Indeed, in contrast to CCR10 (which increases with 
tumor dissemination), we observed a decrease in CXCR4 in 
the blood of patients with lung metastasis, but an accumula­
tion of CXCR4 in metastatic LNs. The CXCR4/CXCL12 axis 
is involved not only in the retention of hematopoietic progen­
prehensive as the present study, in which we include 104 flow 
cytometric parameters, provide correlates between the blood and 
tumor beds, and make functional assessments of defined sub­
sets. In summary, this study (a) unravels, for the first time to our 
knowledge, the orchestrated regulation of CCR/CXCR expres­
sion on peripheral lymphocytes as a function of the metastatic 
pattern of the disease; (b) highlights correlates between CCR/
CXCR expression and OS; (c) unravels the biological significance 
of the CCR9/CCL25 axis in human and murine tumors; and (d) 
highlights new pharmacodynamic parameters (CLA­expressing 
TEMs) during immune checkpoint blockade with ipilimumab 
(Supplemental Table 4).
In a retrospective evaluation of CCR/CXCR expression in 
cytotoxic T lymphocytes (CTLs) from 52 patients with stage III 
or IV MMel, Mullins et al. (18) reported that high expression 
levels of CXCR3 by CD8+CD45RO+ cells were significantly 
associated with enhanced survival in stage III, but not stage IV, 
disease. Here, we confirm that CXCR3 expression is readily lost 
(on CD8+ TNs, TCMs, and CD4+ TCMs) when the skin and LNs 
are invaded, and even more so when distant metastases appear 
and the numbers of CD4+CXCR3+ TEMRAs, TEMs, and TCMs 
are strongly reduced. We found that these cells have the propen­
sity to accumulate in tumor beds and that blockade of CXCR3 in 
mice severely compromises natural cancer immunosurveillance. 
CXCR3+ T cells have been reported to preferentially expand 
post–incomplete Freund’s adjuvant– (post­IFA–) or granulocyte 
Figure 4. CD8+CCR9+ TNs leave the blood during lung metastasis and dic-
tate MMel prognosis. (A) CCR9 expression on CD8+ TNs is depicted for HVs, 
patients presenting with only cutaneous/LN (Cut + LN) metastases, those 
with additional lung (Lung) involvement, those with disseminated disease 
(Multi), and those with distant metastases plus lung involvement (Multi + 
lung) at the time of inclusion. Box plots summarize data from 57 patients 
with MMel and 24 HVs. (B) Match-paired comparison of CCR9 expression 
levels (performed by flow cytometry on fresh tissues) in all CD8+ T cell 
subsets from blood and tumors at the time of surgery in the prospective 
cohort of 20 patients with MMel. (C) Kaplan-Meier survival curves of 57 
patients with MMel according to their proportions of circulating CCR9+CD8+ 
TNs segregated with the median. Each point represents 1 patient specimen, 
and the total number is indicated for all subpopulations studied. Statistical 
analyses were performed by beta regression (A), linear mixed-effects (B), 
and Cox regression (C) modeling. Raw P values are indicated.
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an antiinflammatory phenotype, which would account for the 
tumor progression. In conclusion, disruption of the CCR9/
CCL25 axis in tumor bearers may affect homeostasis of the 
common lymphoid system and compromise the delicate balance 
between gut and systemic immunity (45). Nonetheless, several 
observations point to a cell­autonomous role of CCR9/CCL25 in 
cancer cell migration, invasion, and metastatic dissemination as 
well as in PI3K­dependent resistance to chemotherapy (46–51). 
Enforced CCR9 expression on colorectal cancer cells dictated 
their niching in mouse intestines after xenografting, whereas 
CCL25 blockade enhanced liver metastases (52). Hence, thera­
peutic interventions aimed at disrupting the CCR9/CCL25 axis 
in the context of inflammation­induced carcinogenesis (such 
as in inflammatory bowel disease [IBD]) are worthy of more 
in­depth investigation (53).
CCR10-CTAK/CCL27 interactions may be involved in the 
selective recruitment of CTLs to the skin in a variety of patho­
physiological disorders involving cutaneous tissues such as that 
seen in graft­versus­host disease (54). We observed increased 
recirculation of CCR10­expressing CD4+ TNs, TEMs, and TCMs, 
with or without CRTH2 expression, contrasting with many s.c. 
metastatic lesions. These CCR10+CD4+ T cells harbored a Th9/
Th2/Tr1 phenotype, and high levels were associated with a bad 
prognosis. A recent study reported that CCR10 expression is 
preferentially induced on regulatory memory skin­resident T 
cells, but not on effector cells during an inflammatory skin pro­
cess (55). Other explanations for the high numbers of recircu­
lating CCR10+CD4+ T cells during distant metastases and the 
lack of chemoattraction toward CCL27­producing keratinocytes 
could be the autocrine production of CCL27 by melanoma cells 
themselves (56) or the high serum levels of CCL27, as observed 
in mycosis fungoides (57). Since CCR10­expressing T cells do not 
home to tumors and are endowed with a suppressive cytokine– 
release pattern, it may be useful to interfere with the CCR10/
CCL27 axis with neutralizing Abs.
Immune checkpoint blockade has come of age in the man­
agement of MMel. However, uncoupling efficacy from toxicity 
(skin, gut, and liver) remains an unmet medical need for the 
administration of anti­CTLA4 Abs, alone or in combination with 
PD1/PD-L1 blockade. The dynamic of the skin­homing recep­
tors may be useful for identifying patients prone to respond to 
ipilimumab. Indeed, in a cohort of 47 patients with MMel, the 
induction of CLA expression on CD8+ TEMs after 1 injection was 
associated with disease stabilization or objective responses. It is 
intriguing to note that CLA+ TEMs do not have a natural propen­
sity to accumulate in skin­dLNs in the absence of therapy. How­
ever, it remains to be investigated whether this would be the case 
in patients responding to ipilimumab. Moreover, these findings 
warrant a prospective validation in the context of new­genera­
tion protocols (such as those combining anti­CTLA4 with anti­
PD1 or anti­KIR Abs).
Certain homeostatic chemokine receptors play key roles in 
the homing of various stem cells including tumor cells themselves 
(58). Indeed, CXCR4 is involved in bone, LN, and lung metasta­
ses in breast cancer as well as in melanomagenesis (58). CXCR4 
upregulation also correlated with BRAF mutations in other can­
cers (59). CCR7 and its corresponding ligands CCL19 and CCL21 
itors in the bone marrow, but also in the trafficking of Tregs to 
lesions (34). CXCL12 expression levels in bone and lung met­
astatic niches can be regulated by a variety of inflammatory 
cytokines such as IL­17A, IL­6, and M­CSF (35). Interestingly, 
chemokine receptors also bind factors other than chemokines. 
Noncanonical CXCR4 ligands include the evolutionarily con­
served, proinflammatory macrophage migration inhibitory 
factor (MIF) (36) and the alarmin family member HMGB1, 
which interacts with CXCL12, which may mediate mononu­
clear cell recruitment (37). It is conceivable that these forms 
of nonconventional ligands are present in melanoma­invaded 
lungs. HMGB1 expression by tumor cells has been associated 
with DC and T cell infiltration of lung tumors in a cohort of 
82 patients with advanced non–small­cell lung cancers (38). 
Hence, enforcing the CXCR4­mediated migration of TEMRA 
T cells to lesions (for instance, upon adoptive T cell transfer of 
engineered chimeric antigen receptor–Tg [CAR­Tg] or TCR­Tg 
T cells) could be a strategy for treating MMel.
Our findings indicate that (a) elevated numbers of blood 
CCR9+CD8+ TNs are associated with prolonged survival in 
humans and anticorrelated with tumor size in mice; (b) neutral­
izing CCR9 ligand accelerates the early phase of tumor expo­
nential growth; (c) blockade of CCL25 reduces CD4+ TIL and 
draining LN (dLN) infiltrates; and (d) CCL25 and CXCR3 mod­
ulate immunosurveillance of tumors with different kinetics and 
mechanisms. CCL25 and CCR9 constitute a chemokine­recep­
tor pair that is involved in both T cell development and gut­as­
sociated immune responses (39, 40). CCL25 is indispensable 
for the trafficking of CD8+ TEMs to the epithelium and lamina 
propria of the small intestine, but is dispensable for the prim­
ing in mesenteric LNs that imprints gut­homing properties (41). 
CCR9 is also expressed by Tregs, and CCR9 signaling inhibits 
the differentiation of FOXP3+ T cells (42). CCR9 is upregu­
lated by retinoic acid, which also regulates CD103 expression 
on DCs and primes proinflammatory CD4+ and CD8+ T cells 
in the mesenteric LNs for their homing to intestinal mucosa. 
In the present study, circulating CCR9+CD8+ TNs or TCMs did 
not correlate with metastases in the gut or peritoneum. Instead, 
they tended to accumulate in primary tumors and, to a lesser 
extent, in metastatic LNs in mice and humans. Neutralization of 
CCL25 did not reduce tumor infiltration by CD4+CCR9+ TEMs 
(data not shown), but reduced CD4+ TIL content (Figure 7F) 
and significantly augmented the recirculation of CD4+CCR9+ 
TEMs and TCMs into the spleen (data not shown), perhaps 
facilitating their passive homing to the gut. Supporting this 
assumption, effector Th1 cells generated from a previous viral 
lung infection could cause intestinal damage following CCR9/
CCL25­dependent trafficking of Th1 cells to the small intes­
tine and their IL-15Rα–dependent transdifferentiation into 
pathogenic Th17 cells (43). Likewise, macrophages can express 
CCR9 and become proinflammatory after ligation with CCL25, 
producing TNF­α and activating hepatic stellate cells to eventu­
ally accelerate concanavalin A–induced (Con A–induced) acute 
hepatitis (44). In our model, interruption of crosstalk between 
intratumoral macrophages and CD4+ TILs following infusion of 
anti­CCL25 Abs may have impaired TNF­α production by mac­
rophages and hence reset the tumor microenvironment toward 
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functions were included in the SORAFTEM phase I/II investigator­
sponsored study. T cell analyses were performed on peripheral blood 
mononuclear cells (PBMCs) from patients’ blood samples drawn 
prior to temozolomide and sorafenib treatment.
LUDWIG: MAGE3 protein–based vaccines. Details on patient char­
acteristics, protocol description, and survival have been previously 
reported by Kruit et al. (64). T cells were analyzed at the start of the 
study, prior to vaccine inoculation (1 month after relapse with conven­
tional therapies), and correlated with OS.
IMAIL-2 study. Adult patients with solid malignancy or measur­
able or evaluable disease and who were refractory to standard therapy 
were eligible for the study (IMAIL-2 phase I trial). The IMAIL-2 trial 
and its participating patients have been previously described, and T 
cell analyses were performed prior to cyclophosphamide, IL-2, and 
imatinib treatment (65). The clinical characteristics of these 3 cohorts 
are described in detail in Supplemental Table 2.
The ipilimumab-treated cohorts included 47 patients with MMel  
from 4 centers
Prospective French cohort of 22 patients. All patients had stage IIIB/
IV MMel and were treated at the Gustave Roussy Cancer Cam­
pus between March 2013 and October 2014. Blood samples were 
drawn from patients before and after 1, 2, 3, and 4 cycles of ipili­
mumab treatment. Patients’ samples were provided by C. Robert, 
N. Chaput, C. Coutzac, and S. Cotteret (Gustave Roussy Institute, 
Villejuif, France).
Retrospective German cohort of 4 patients. Blood was collected, 
before and after 2 ipilimumab injections, from 4 patients partici­
pating in a phase II study evaluating the safety and efficacy of com­
bined ipilimumab and intratumoral IL­2 treatment in pretreated 
patients with stage IV melanoma (ClinicalTrials.gov identifier: 
NCT01480323). Chemokine receptors were assessed in patients 
at baseline and after 2 injections of ipilimumab with concomitant 
treatment consisting of 7 or 8 injections of intratumoral IL­2 (9 
mIU/injection).
Retrospective Italian cohort of 10 patients. Blood samples were 
collected from patients before and after 1 and 2 injections of ipili­
mumab at the University Hospital of Siena between July 2011 and 
June 2015. The chemokine receptor profile was assessed after the 
samples were thawed.
Retrospective American cohort of 11 patients. Blood samples were 
collected from patients before and after 2 injections of ipilimumab 
(ClinicalTrials.gov identifier: NCT00495066). The chemokine 
receptor profile was assessed after the samples were thawed. Clinical 
characteristics of these 4 cohorts are described in detail in Supple­
mental Table 3.
Prospective cohort of 20 patients with stage III/IV  
metastatic melanoma
Blood and metastatic LNs were collected at the time of surgery at 
the Gustave Roussy Cancer Center or at the CHU (Lyon, France) 
between May 2013 and March 2015 and were processed as men­
tioned below. Eighty­six percent of patients presented with stage III 
disease at sampling. Two stage IV patients presented with pulmo­
nary metastases, and a third patient had abdominal metastases. Five 
patients (23%) were treated before sampling with DTIC (dacarba­
zine), IFN­α, or tyrosine kinase inhibitors.
have been associated with LN metastases,  the CCR10/CCL27 
axis with melanoma skin survival and metastases (29), and the 
CCR9-CCL25 interaction in metastases in the small intestine 
(28). Finally, CXCR3 expression in cutaneous melanoma cells 
negatively correlates with lymphocyte infiltration (60). Hence, it 
is conceivable that there could be a competition for ligand access 
between malignant cells and host leukocytes. This notion is partic­
ularly important with regard to therapeutic targeting. Indeed, an 
impairment of CXCR4/CXCL12­driven chemotaxis by AMD3100 
or AMD11070 could inhibit skin tumor development (by mast cell 
suppression) and block liver melanoma metastases (61) on the one 
hand, but could prevent trafficking of T cells into lesions on the 
other hand. Thus, by inhibiting antigen­mediated T cell accumu­
lation in the small intestine (62), the CCR9 antagonist CCX8037 
could interfere with the natural immunosurveillance against mel­
anoma. Therefore, our data should prompt detailed investigations 
into how these drugs affect lymphocyte trafficking (53).
In conclusion, specific CCR/CXCR expression patterns on 
circulating T lymphocytes may guide novel diagnostic and ther­
apeutic approaches in the context of MMel. In the future, it will 
be important to investigate the dynamic expression of CCR/
CXCR ligands as well as expression of CCR/CXCR by melanoma 
cells during immunotherapy or targeted therapy, with the aim of 
gaining even more clinically relevant information on the dialog 
between malignant cells and their microenvironment.
Methods
Characteristics of patients and cohorts
SORAFTEM. The SORAFTEM (European Union Drug Regulating 
Authorities clinical trial EudraCT 2007-000527-18) cohort has been 
described previously (63). Patients over 18 years of age with histolog­
ically confirmed metastatic or unresectable melanoma, measurable 
disease, an Eastern Cooperative Oncology Group performance status 
below 2, and adequate hematologic, renal, hepatic, and coagulopathic 
Figure 5. Levels of CD4+CCR10+ TEMs and CCR10+CLA+ T cells mod-
ulated by distant metastases dictate MMel prognosis. (A) CCR10 
expression on CD4+ TEMs is depicted for HVs and patients presenting 
with only cutaneous/LN (Cut + LN) metastases, additional lung (Lung) 
involvement, disseminated disease (Multi), and distant metastases 
plus lung involvement (Multi + lung) at the time of inclusion in 1 of the 
3 protocols described in the Methods. (B) Match-paired comparisons 
of CCR10 expression (performed by flow cytometry) in all CD4+ T cell 
subsets from blood and tumors at the time of surgery in the prospec-
tive cohort of 20 patients with MMel. (C) CD4+CCR10+ T cell cytokine 
profile. Flow cytometry–guided sorting based on CCR10 expression in 
blood CD4+ T cells in 1 representative patient (out of 2 yielding similar 
results) to analyze cytokine release after a 40-hour CD3/CD28 bead–
driven stimulation. (D) Kaplan-Meier survival curves of 57 patients 
with MMel according to the median of their proportions of circulating 
CD4+CCR10+ TEMs (of note, identical results with TCMs are not shown). 
(E and F) Same as as in B and C, showing the subset of double-positive 
CCR10+CLA+CD4+ T cells. (G) Same as in D, analyzing OS as a function 
of CCR10/CLA CD4+ T cell subsets. Each point represents 1 patient 
specimen, and the total number is indicated for all subpopulations 
studied. Statistical analyses were performed by beta regression (A), 
linear mixed-effects (B and E), and Cox regression (D and G) modeling. 
Raw P values are indicated.
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medium, which consisted of RPMI 1640, 1% penicillin­streptomy­
cin, type IV collagenase (50 IU/ml), hyaluronidase (280 IU/ml), and 
DNAse I (30 IU/ml) (all from Sigma­Aldrich) and were run on a gen­
tleMACS Dissociator (Miltenyi Biotec). The cell samples were diluted 
in PBS and then passed through a cell strainer and centrifuged for 5 
minutes at 450 g. Next, cells were resuspended in PBS and stained for 
flow cytometric analysis.
Flow cytometric analyses
Human study. PBMCs and TILs were stained with fluorochrome­cou­
pled mAbs (detailed in Supplemental Table 1), incubated for 20 
minutes at 4°C, and then washed. Cell samples were acquired with 
a multicolor Cyan ADP 9 Color Flow Cytometer (Beckman Coulter). 
For compensations, single­stained Ab­capturing beads were used 
(Compbeads; BD Biosciences). Data were analyzed with FlowJo 
software, version 7.6.5. For dead­cell discrimination and to exclude 
B cells, NK cells, and macrophages or neutrophils, a dump channel 
with a LIVE/DEAD Cell­Staining Kit (Invitrogen, Life Technologies) 
and CD14, CD15, CD16, and CD19 mAbs were used. To discriminate 
between the different subsets of lymphocytes, T cells were stained 
with CD4, CD8, CCR7, CD45RA, CRTH2, CCR10, CXCR3, CCR6, 
CXCR5, CD103, CCR9, CLA, and CXCR4 mAbs (see Supplemental 
Figure 1 for the gating strategy). Of note, 2 tubes containing the same 
CCR10 Ab assessing different additional markers in each tube of 
flow cytometric staining were featured on the graphs as CCR10 and 
CCR10.2 (but significant correlations between the 2 tubes for CCR10 
expression levels were found).
Mouse study. The following fluorescence­labeled mAbs were 
used: anti–CD3-PerCP-Cy5.5, anti–CD4-PE-Cy7, anti–CD8-AP­
C-Cy7, and anti–CD62L-APC (all from BD Biosciences); and anti–
CD45RB-APC-Cy7, anti–CD183-PE, anti–CD199-FITC, and anti–
CD44-PE-Cy7 (all from BioLegend). Single­cell suspensions were 
treated with FcR Blocking Reagent (Miltenyi Biotec) for 15 minutes at 
4°C, followed by incubation with mAbs for 30 minutes at 4°C. Acqui­
sition was performed by 6­color flow cytometry using the FACSCanto 
II with FACSDiva version 6.0 software, which includes the Cytometer 
Setup and Tracking System (both from BD Biosciences). Dead­cell 
exclusion was based on scatter profile or 7-AAD (BioLegend). The 
compensation control was performed with a BD CompBeads set (BD 
Biosciences) following the manufacturer’s instructions. FlowJo soft­
ware was used to analyze samples.
Cell-sorting and T cell polarization analyses
Frozen PMBCs and/or TILs were quickly thawed in culture media, 
washed in sorting media (PBS supplemented with 10% FCS; PAA 
Laboratories) and 1 mM EDTA (Research Organics Inc.) and resus­
pended after filtration through a cell strainer. Cells were stained with 
the appropriate mAbs (see Supplemental Table 1) and sorted by flow 
cytometry on a 3­laser FACSAria III Cell Sorter (BD) or on a 3­laser 
MoFlo XDP Cell Sorter (Beckman Coulter). Sorted positive and neg­
ative cell populations were washed and resuspended in culture media 
and seeded in a 96­well plate with 20 UI/ml IL-2 (Proleukin) and 
stimulated with Dynabeads Human T-Activator CD3/CD28 (Gibco, 
Life Technologies) according to the manufacturer’s instructions. 
After 40 hours, supernatants were collected and frozen at –20°C until 
cytokine dosage with a Human Th1/Th2/Th9/Th17/Th22 13­plex 
RTU FlowCytomix Kit (eBioscience) according to the manufacturer’s 
Mice
C57Bl/6 mice expressing the human RET transgene in melanocytes 
under control of the murine metallothionein I promoter enhancer 
were provided by I. Nakashima (Chubu University, Aichi, Japan). 
Animals were crossed and kept under specific pathogen–free (SPF) 
conditions in the animal facility at the German Cancer Research 
Center (Heidelberg, Germany). All mice studied were between 5 
and 7 weeks of age and had visible macroscopic tumors of different 
sizes. For s.c. tumors in the MCA205 model, mice between 7 and 
14 weeks of age were used. WT SPF C57BL/6J mice were obtained 
from Harlan Laboratories and were kept in SPF conditions at the 
Gustave Roussy Institute. The murine fibrosarcoma MCA205 cell 
line was cultured at 37°C in 5% CO2 in RPMI 1640 medium sup­
plemented with 10% heat­inactivated FBS, 100 U/ml penicillin G 
sodium, 100 μg/ml streptomycin sulfate, 2 mM L­glutamine, 1 mM 
sodium pyruvate, and nonessential amino acids (all reagents from 
Gibco, Invitrogen). Mice were s.c. injected into the right flank with 
0.8 million cells and i.p. with anti­CCL25 Ab (100 μg/mouse; clone 
89818; R&D Systems); anti­CXCR3 (200 μg/mouse; clone CXCR3­
173; BioXcell); and their respective isotype controls the same day 
but several hours before tumor inoculation and every 3 days for 5 
injections. Organs were collected, digested, counted, and stained 
with the appropriate Abs, as described below.
PBMC preparations
PBMCs were thawed and washed in culture medium (SORAFTEM, 
IMAIL­2, LUDWIG, German, Italian, and American cohorts), i.e., 
RPMI 1640 (Gibco, Invitrogen), 10% human AB+ serum (Institut de 
Biotechnologies Jacques Boy), 1% penicillin/streptomycin (PEST; 
Gibco, Invitrogen), and 2 mM L­glutamine (Gibco, Invitrogen). 
Peripheral blood samples from patients (prospective cohorts) were 
carefully layered on top of a Ficoll­Hypaque density gradient (PAA 
Laboratories). PBMCs were collected and washed twice in Dulbec­
co’s PBS (Gibco, Invitrogen), followed by resuspension in PBS. Cells 
were then stained for flow cytometric analyses or resuspended in 
CryoMaxx medium (PAA Laboratories) for storage in liquid nitro­
gen. No significant differences between handling of cells from HVs 
versus those from patients could be detected in these processes.
TIL preparations
Resected LN specimens from 20 patients with MMel were analyzed 
for infiltrating lymphocyte phenotyping in parallel with paired­blood 
specimens. Tissue samples were cut and placed into dissociation 
Figure 6. Ipilimumab-induced CLA+CD8+ TEMs are associated with 
favorable clinical outcome. Absolute numbers (A, left) and propor-
tions (B, left) of CLA-expressing CD8+ TEMs over time (left panel) are 
depicted for a cohort of 47 ipilimumab-treated patients with MMel and 
then segregated by nonresponders (NR) and responders (R) evaluated 3 
months (4 injections) after commencement of therapy. (A and B, right 
panels) Receiver operating characteristics (ROC) curves depicting the 
predictive properties of each parameter determined after 1 ipilimumab 
injection and associated with the AUC. (C and D) Same as in A and B, 
except C shows the absolute number and D the proportions of CLA-
expressing CD4+ TEMs. Each point represents 1 patient specimen, and 
the total number is indicated for all subpopulations studied. Statistical 
analyses were performed by logistic regression and adjusted according 
to the study center.
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after adjusting for investigation center differences. Significance levels 
were determined by P values with up to 4 digits and adjusted according 
to the Benjamini­Hochberg (expressed as the FDR) or Holm (denoted 
by symbols in the graphs) method. Unless otherwise stated, P values 
are 2­sided, and 95% CIs for the statistic of interest are reported.
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instructions and acquired on a multicolor CyAn ADP 9 Color Flow 
Cytometer (Beckman Coulter). Analyses were performed using Flow­
Cytomix Pro 3.0 Software (eBioscience).
Protein dosage
CCL25 dosage was done using a commercially available ELISA kit (R&D 
Systems) following the manufacturer’s recommendations. This concen­
tration was normalized to the total protein content as measured by the 
DC protein assay (Bio­Rad) following the manufacturer’s protocol.
Statistics
Data were analyzed and presentations were performed within the R 
statistical environment (66). Flow cytometric parameters were con­
verted to Z­scores prior to any correlation analyses. The estimation of 
metastatic group effect (human data) and organ distributions (mouse 
data) on FACS parameters was performed by beta regression mod­
eling, with the dispersion allowed to differ between groups. For the 
other continuous parameters, generalized least­squares regression 
was applied to log­transformed data and contrasts of interest tested 
by Wald tests. Parameter distributions between the blood and tumor 
were assessed by mixed­effects linear modeling. OS, determined 
from the date of diagnosis, and progression­free survival (PFS), deter­
mined from the date of sampling, were used as the primary endpoints. 
Survival curves were estimated by the Kaplan­Meier product­limit 
method. Survival distributions were compared by Firth’s penalized 
likelihood Cox regression after adjusting for metastatic location or 
stage. The predictive abilities of individual markers for the response of 
patients to ipilimumab treatment were evaluated by logistic regression 
Figure 7. Neutralizing CCL25 or CXCR3 independently impacted tumor 
progression. (A and B) Naive and memory CD4+ and CD8+ T cells from RET- 
induced mouse melanomas, metastatic LNs, and spleens analyzed by multi-
color flow cytometry. TNs were characterized as CD4+CD45RB+ and CD8+CD44lo, 
central memory (CM), CD4+CD45RB–CD62L+, and CD8+CD44hiCD62L+ cells, 
while effector memory (EM) cells were defined as CD4+CD45RB–CD62L– and 
CD8+CD44hiCD62L– cells. Cumulative data showing expression levels of CCR9 
and CXCR3 are depicted as percentages of the respective cell subset within live 
total CD4+ or CD8+ T cells from 3 independent experiments in the 3 locations. 
(C) Frequencies of CD8+CD44loCCR9+ T cells within total live CD8+ T cells 
in skin lesions in relation to the skin tumor weight (n = 11, 3 independent 
experiments). (D) Ex vivo explanted MCA205 sarcoma tumor as well as gut 
explants were dosed for CCL25 and normalized to total protein content.  
(E) MCA205 cells were inoculated in C57BL/6 mice that were concomitantly 
treated with i.p. administration of anti-CCL25 Ab, positive control anti-
CXCR3 Ab, and their respective isotype controls (Iso) (5 injections, every 3 
days). Tumor sizes were monitored until sacrifice and are depicted at day 6 
(left panel) and day 17 (right panel) from 2 independent experiments.  
(F and G) Flow cytometric monitoring of CD4+ and CD8+ T cells in tumor 
beds (left panel) and tumor-dLNs (right panel) after neutralization of 
CCL25 or CXCR3 at the time of sacrifice (day 13). Each point represents 
1 specimen, and the total number is indicated for all subpopulations 
studied. Statistical analyses were performed by beta regression (A and 
B), linear mixed-effects (D, F, and G), and linear (D and E) modeling, or by 
Spearman’s test. Raw P values are indicated.
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